Analysis, trial results, and regulatory news on retatrutide (LY3437943), Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist.https://retatrutide.med/en-ushttps://retatrutide.med/blog/retatrutide-black-market-crackdown-2026/https://retatrutide.med/blog/retatrutide-black-market-crackdown-2026/Lilly sued six sellers, the FDA named 'GLP-3 Reta' in warning letters, grey-market users lost half the trial weight, and a counterfeit vial was 8x semaglutide.Wed, 16 Sep 2026 00:00:00 GMTnewsgray marketblack marketcounterfeitFDA warning letterEli Lilly lawsuitTGAhttps://retatrutide.med/blog/retatrutide-expanded-access-program/https://retatrutide.med/blog/retatrutide-expanded-access-program/Lilly's pre-approval program (NCT07629401): BMI 35+ despite maximal approved therapy, two serious complications, no accessible trial. Physician-requested only.Wed, 16 Sep 2026 00:00:00 GMTregulatoryexpanded accesscompassionate usehow to get retatrutideclinical trialsEli LillyFDAhttps://retatrutide.med/blog/triumph-2-triumph-3-results/https://retatrutide.med/blog/triumph-2-triumph-3-results/Eli Lilly's July 23, 2026 readouts: -20.8% weight loss with type 2 diabetes, -22.6% with cardiovascular disease, dysesthesia 6-7%, and a BLA planned for Q1 2027.Thu, 23 Jul 2026 00:00:00 GMTnewsTRIUMPH-2TRIUMPH-3Phase 3retatrutidetype 2 diabetescardiovascular diseasehttps://retatrutide.med/blog/synergy-outcomes-maceld-mash-explained/https://retatrutide.med/blog/synergy-outcomes-maceld-mash-explained/How retatrutide targets MASH liver disease: the glucagon-driven liver-fat effect, plus what the SYNERGY-OUTCOMES and MACELD Phase 3 trials aim to prove.Wed, 22 Jul 2026 00:00:00 GMTanalysissynergy-outcomesmaceldmashmasldretatrutideliver diseasehttps://retatrutide.med/blog/how-was-retatrutide-discovered/https://retatrutide.med/blog/how-was-retatrutide-discovered/Retatrutide was built by adding glucagon action to the GIP/GLP-1 backbone behind tirzepatide. Inside the discovery science of the first triple agonist.Tue, 21 Jul 2026 00:00:00 GMTanalysisretatrutidetriple agonistdrug discoveryglucagon receptorpeptide engineeringmechanism of actionhttps://retatrutide.med/blog/when-was-retatrutide-created/https://retatrutide.med/blog/when-was-retatrutide-created/Retatrutide entered human trials in 2019, about 7 years ago. A year-by-year timeline from its 2016 design to 2026 Phase 3 data — still investigational.Mon, 20 Jul 2026 00:00:00 GMTanalysisretatrutide historytimelinewhen was retatrutide createddrug developmenteli lillyly3437943https://retatrutide.med/blog/retatrutide-ada-2026-triumph-transcend/https://retatrutide.med/blog/retatrutide-ada-2026-triumph-transcend/At the ADA 2026 Scientific Sessions (June 6), retatrutide's pivotal TRIUMPH-1 obesity and TRANSCEND-T2D-1 diabetes results were presented in full — with TRANSCEND-T2D-1 published simultaneously in The Lancet. Beyond weight loss, nested baskets showed 73.1% knee-pain and 60.6% sleep-apnea reductions.Tue, 09 Jun 2026 00:00:00 GMTconference-coverageADA 2026TRIUMPH-1TRANSCEND-T2D-1The Lancetretatrutideobesityhttps://retatrutide.med/blog/triumph-1-bariatric-level-results/https://retatrutide.med/blog/triumph-1-bariatric-level-results/Eli Lilly's pivotal TRIUMPH-1 Phase 3 trial of retatrutide (May 21, 2026) reported 28.3% mean weight loss at 12 mg over 80 weeks, with 45.3% of participants losing 30%+ of body weight. Full results, safety profile, and what it means for the regulatory timeline.Fri, 22 May 2026 00:00:00 GMTnewsTRIUMPH-1Phase 3retatrutideweight lossEli Lillypivotal trialhttps://retatrutide.med/blog/next-gen-obesity-drugs-compared/https://retatrutide.med/blog/next-gen-obesity-drugs-compared/Comparing retatrutide, orforglipron, amycretin, MariTide, survodutide, and VK2735 — mechanisms, efficacy data, and timelines as of April 2026.Fri, 03 Apr 2026 00:00:00 GMTanalysisobesity drugspipelineorforglipronamycretinMariTidesurvodutidehttps://retatrutide.med/blog/retatrutide-diet-nutrition/https://retatrutide.med/blog/retatrutide-diet-nutrition/What to eat on retatrutide, how much protein you need, hydration strategies, and micronutrients to watch — based on clinical trial data.Fri, 03 Apr 2026 00:00:00 GMTanalysisdietnutritionproteinlean massside effectsmeal planninghttps://retatrutide.med/blog/retatrutide-drug-interactions/https://retatrutide.med/blog/retatrutide-drug-interactions/Analysis of potential retatrutide drug interactions based on GLP-1 class effects, including oral contraceptives, metformin, insulin, and anticoagulants.Fri, 03 Apr 2026 00:00:00 GMTanalysisdrug interactionsmetforminbirth controloral contraceptivesinsulinwarfarinhttps://retatrutide.med/blog/retatrutide-hair-loss/https://retatrutide.med/blog/retatrutide-hair-loss/Is retatrutide causing hair loss? A look at telogen effluvium during rapid weight loss, GLP-1 trial data, and what you can do about it.Fri, 03 Apr 2026 00:00:00 GMTanalysishair losstelogen effluviumside effectsGLP-1weight lossnutritionhttps://retatrutide.med/blog/retatrutide-sleep-apnea/https://retatrutide.med/blog/retatrutide-sleep-apnea/Clinical analysis of retatrutide's potential for obstructive sleep apnea based on TRIUMPH-2 protocols, tirzepatide precedent, and weight-loss-driven mechanisms.Fri, 03 Apr 2026 00:00:00 GMTanalysissleep apneaOSATRIUMPH-2ZepboundtirzepatideAHIhttps://retatrutide.med/blog/retatrutide-weight-regain/https://retatrutide.med/blog/retatrutide-weight-regain/Analysis of weight regain risk after stopping GLP-1 therapies and what retatrutide's TRIUMPH program tells us about long-term maintenance dosing.Fri, 03 Apr 2026 00:00:00 GMTanalysisweight regainmaintenance dosingTRIUMPH-1TRIUMPH-2discontinuationGLP-1https://retatrutide.med/blog/retatrutide-online-risks-gray-market/https://retatrutide.med/blog/retatrutide-online-risks-gray-market/Retatrutide is widely available from online 'research peptide' vendors, but these products carry significant safety risks. This article explains why gray-market retatrutide is dangerous, what FDA enforcement actions have occurred, and why clinical-grade manufacturing matters.Wed, 18 Mar 2026 00:00:00 GMTanalysisgray marketresearch peptidessafetyFDAcompoundingcontaminationhttps://retatrutide.med/blog/retatrutide-pricing-analysis/https://retatrutide.med/blog/retatrutide-pricing-analysis/No price announced for retatrutide, but tirzepatide pricing, the biologic lawsuit, analyst projections, and Lilly's $3.5B plant offer clues on future cost.Wed, 18 Mar 2026 00:00:00 GMTanalysispricingcostEli Lillytirzepatideanalyst projectionsbiologichttps://retatrutide.med/blog/retatrutide-uk-europe-availability/https://retatrutide.med/blog/retatrutide-uk-europe-availability/Retatrutide is not approved in the UK or EU as of 2026. Covers MHRA and EMA pathways, expected timelines (late 2028 UK, 2029 EU), and NICE assessment.Wed, 18 Mar 2026 00:00:00 GMTregulatoryUKEuropeMHRAEMANICEregulatoryhttps://retatrutide.med/blog/retatrutide-dose-escalation-explained/https://retatrutide.med/blog/retatrutide-dose-escalation-explained/Understanding dose escalation in retatrutide and other GLP-1 class drugs — how gradual titration improves tolerability, what the Phase 2 trial revealed, and implications for clinical practice.Tue, 17 Mar 2026 00:00:00 GMTanalysisretatrutidedose escalationGLP-1tolerabilitygastrointestinal side effectsclinical practicehttps://retatrutide.med/blog/retatrutide-dysesthesia-what-we-know/https://retatrutide.med/blog/retatrutide-dysesthesia-what-we-know/A clinical analysis of the dysesthesia signal observed in retatrutide's TRIUMPH-4 Phase 3 trial — incidence rates, severity, potential mechanisms, and what it means for regulatory review.Tue, 17 Mar 2026 00:00:00 GMTanalysisdysesthesiaside effectsTRIUMPH-4Phase 3safetynerve sensationhttps://retatrutide.med/blog/retatrutide-liver-fat-masld-potential/https://retatrutide.med/blog/retatrutide-liver-fat-masld-potential/An analysis of retatrutide's liver fat reduction data from Phase 2 imaging substudies, the role of glucagon receptor agonism in hepatic lipid metabolism, and the implications for MASLD/MASH as a therapeutic indication.Tue, 17 Mar 2026 00:00:00 GMTanalysisliver fatMASLDMASHNAFLDfatty liverglucagon receptorhttps://retatrutide.med/blog/retatrutide-muscle-preservation-what-data-shows/https://retatrutide.med/blog/retatrutide-muscle-preservation-what-data-shows/An evidence-based analysis of retatrutide's Phase 2 body composition substudy, examining the ratio of fat mass to lean mass loss and what it means for clinical outcomes.Tue, 17 Mar 2026 00:00:00 GMTanalysismuscle preservationbody compositionlean massfat massDEXAPhase 2https://retatrutide.med/blog/retatrutide-phase-3-vs-phase-2-dosing/https://retatrutide.med/blog/retatrutide-phase-3-vs-phase-2-dosing/An analysis of the key differences between retatrutide's Phase 2 and Phase 3 dose escalation protocols, the clinical rationale behind the changes, and what they signal about Eli Lilly's regulatory strategy.Tue, 17 Mar 2026 00:00:00 GMTanalysisdose escalationPhase 2Phase 3TRIUMPHtitrationtolerabilityhttps://retatrutide.med/blog/future-of-obesity-pharmacotherapy/https://retatrutide.med/blog/future-of-obesity-pharmacotherapy/Where obesity treatment is headed — the evolution from GLP-1 monotherapy to multi-receptor agonists and combination strategies, and where retatrutide fits in the expanding pipeline.Thu, 05 Mar 2026 00:00:00 GMTopinionobesitypharmacotherapyGLP-1retatrutidepipelineCagriSemahttps://retatrutide.med/blog/liver-fat-reduction-breakthrough/https://retatrutide.med/blog/liver-fat-reduction-breakthrough/An in-depth analysis of retatrutide's approximately 82% liver fat reduction in Phase 2 — what it means for MASLD treatment, why glucagon receptor agonism drives the effect, and how it compares to other therapeutic approaches.Wed, 14 Jan 2026 00:00:00 GMTanalysisliver fatMASLDNAFLDhepatic steatosisMRI-PDFFglucagonhttps://retatrutide.med/blog/weight-loss-percentages-in-context/https://retatrutide.med/blog/weight-loss-percentages-in-context/What does 28.7% mean body weight loss actually look like in clinical practice? Contextualizing retatrutide Phase 3 data against bariatric surgery, lifestyle intervention, and responder analysis.Thu, 18 Dec 2025 00:00:00 GMTanalysisretatrutideweight lossbariatric surgeryclinical contextresponder analysisobesity treatmenthttps://retatrutide.med/blog/retatrutide-approval-timeline/https://retatrutide.med/blog/retatrutide-approval-timeline/Updated September 2026: all five pivotal trials reported, BLA planned for Q1 2027, earliest FDA decision late 2027 (Priority Review) or the first half of 2028.Wed, 05 Nov 2025 00:00:00 GMTregulatoryFDA approvalregulatoryNDAtimelineEli Lillydrug developmenthttps://retatrutide.med/blog/retatrutide-vs-mounjaro-same-company/https://retatrutide.med/blog/retatrutide-vs-mounjaro-same-company/How Eli Lilly is developing both tirzepatide (Mounjaro/Zepbound) and retatrutide — examining dual vs. triple agonism, clinical differentiation, and portfolio strategy.Mon, 03 Nov 2025 00:00:00 GMTanalysisretatrutidetirzepatideMounjaroZepboundEli LillyGIPhttps://retatrutide.med/blog/retatrutide-vs-wegovy-what-data-shows/https://retatrutide.med/blog/retatrutide-vs-wegovy-what-data-shows/A cross-trial comparison of retatrutide and semaglutide 2.4 mg (Wegovy), examining weight loss efficacy, mechanism differences, and the limitations of indirect comparisons.Fri, 12 Sep 2025 00:00:00 GMTanalysisretatrutidesemaglutideWegovyweight losscross-trial comparisonGLP-1https://retatrutide.med/blog/retatrutide-side-effects-what-studies-show/https://retatrutide.med/blog/retatrutide-side-effects-what-studies-show/A factual, evidence-based summary of adverse events reported in retatrutide Phase 1 and Phase 2 clinical trials — gastrointestinal effects, dose-dependent patterns, discontinuation rates, and how they compare to other incretin-based therapies.Fri, 22 Aug 2025 00:00:00 GMTanalysisside effectsadverse eventssafetytolerabilityGI effectsclinical trialshttps://retatrutide.med/blog/triumph-program-explained/https://retatrutide.med/blog/triumph-program-explained/A comprehensive guide to Eli Lilly's TRIUMPH clinical trial program for retatrutide — individual trial designs, enrollment targets, primary endpoints, expected timelines, and what it all means for potential regulatory approval.Tue, 10 Jun 2025 00:00:00 GMTanalysisTRIUMPHPhase 3clinical trialsEli Lillyregulatory pathwayobesityhttps://retatrutide.med/blog/why-glucagon-receptor-matters/https://retatrutide.med/blog/why-glucagon-receptor-matters/An analysis of why adding glucagon receptor agonism to GLP-1 and GIP activity makes retatrutide mechanistically distinct — and how glucagon's effects on energy expenditure, liver fat metabolism, and thermogenesis may drive superior clinical outcomes.Fri, 18 Apr 2025 00:00:00 GMTanalysisglucagonglucagon receptorenergy expenditurethermogenesisliver fatmechanism of actionhttps://retatrutide.med/blog/what-phase-3-means/https://retatrutide.med/blog/what-phase-3-means/An explanation of what Phase 3 clinical trials represent in drug development, what the TRIUMPH program is designed to answer, and what stakeholders should expect from retatrutide's pivotal trials.Tue, 01 Oct 2024 00:00:00 GMTanalysisPhase 3TRIUMPHclinical developmentFDApivotal trialshttps://retatrutide.med/blog/understanding-triple-agonism/https://retatrutide.med/blog/understanding-triple-agonism/An analysis of why targeting three metabolic hormone receptors simultaneously represents a meaningful advancement over single and dual agonist approaches, and what it means for the future of obesity and diabetes treatment.Sun, 01 Sep 2024 00:00:00 GMTanalysistriple agonismincretin therapymetabolic medicineGLP-1GIPglucagonhttps://retatrutide.med/blog/glp1-revolution-context/https://retatrutide.med/blog/glp1-revolution-context/How retatrutide fits into the broader GLP-1 revolution that is transforming metabolic medicine, and what the competitive landscape means for the future of obesity and diabetes treatment.Thu, 15 Aug 2024 00:00:00 GMTnewsGLP-1market landscapesemaglutidetirzepatideobesity treatmentmetabolic medicinehttps://retatrutide.med/blog/phase-2-results-breakdown/https://retatrutide.med/blog/phase-2-results-breakdown/A detailed analysis of retatrutide's Phase 2 obesity trial data published in the New England Journal of Medicine, explaining what the key endpoints and results signify for the field.Mon, 15 Jul 2024 00:00:00 GMTanalysisPhase 2obesityNEJMweight lossclinical trial resultsdata analysishttps://retatrutide.med/blog/reading-clinical-trial-data/https://retatrutide.med/blog/reading-clinical-trial-data/An educational guide explaining how to interpret clinical trial results, including endpoints, statistical significance, effect sizes, and common pitfalls, using examples from metabolic medicine research.Sat, 15 Jun 2024 00:00:00 GMTanalysisclinical trialseducationstatisticsendpointsevidence-based medicine